Jounce Therapeutics (Jounce Therapeutics) Debt-to-EBITDA : 0.05 (As of Dec. 2022)

View and export this data going back to 2017. Start your Free Trial

What is Jounce Therapeutics Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Jounce Therapeutics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2022 was $4.15 Mil. Jounce Therapeutics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2022 was $5.87 Mil. Jounce Therapeutics's annualized EBITDA for the quarter that ended in Dec. 2022 was $203.12 Mil. Jounce Therapeutics's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2022 was 0.05.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Jounce Therapeutics's Debt-to-EBITDA or its related term are showing as below:

JNCE' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -0.41 Med: -0.18 Max: 0.35
Current: -0.2

During the past 9 years, the highest Debt-to-EBITDA Ratio of Jounce Therapeutics was 0.35. The lowest was -0.41. And the median was -0.18.

JNCE's Debt-to-EBITDA is not ranked
in the Biotechnology industry.
Industry Median: 1.37 vs JNCE: -0.20

Jounce Therapeutics Debt-to-EBITDA Historical Data

The historical data trend for Jounce Therapeutics's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Jounce Therapeutics Debt-to-EBITDA Chart

Jounce Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Debt-to-EBITDA

Get a 7-Day Free Trial

0.35

-0.41

-0.16

-0.20

Jounce Therapeutics Quarterly Data
	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22
Debt-to-EBITDA	Get a 7-Day Free Trial															-0.12	-0.09	-0.09	-0.09	0.05

Competitive Comparison of Jounce Therapeutics's Debt-to-EBITDA

For the Biotechnology subindustry, Jounce Therapeutics's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Jounce Therapeutics's Debt-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Jounce Therapeutics's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Jounce Therapeutics's Debt-to-EBITDA falls into.

Jounce Therapeutics Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Jounce Therapeutics's Debt-to-EBITDA for the fiscal year that ended in Dec. 2022 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(4.15	+	5.87)	/	-50.155
	=	-0.20

Jounce Therapeutics's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2022 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(4.15	+	5.87)	/	203.124
	=	0.05

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Dec. 2022) EBITDA data.

Jounce Therapeutics (NAS:JNCE) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.

Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

Jounce Therapeutics Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Jounce Therapeutics's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.

Jounce Therapeutics (Jounce Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Jounce Therapeutics Inc (NAS:JNCE) » Definitions » Debt-to-EBITDA

Comparable Companies

Traded in Other Exchanges

N/A

Address

780 Memorial Drive, Cambridge, MA, USA, 02139

Website

https://www.jouncetx.com

Jounce Therapeutics Inc is a clinical stage immunotherapy company. It is engaged in developing therapies that enable the immune system to attack tumors and provide long-lasting benefits to patients. The company primarily operates only in the United States. The company has developed a suite of integrated technologies that comprise a Translational Science Platform, enabling it to comprehensively interrogate the cellular and molecular composition of tumors.

Executives

Concentra Merger Sub, Inc.	10 percent owner	4747 EXECUTIVE DRIVE, SUITE 210, SAN DIEGO CA 92121
Concentra Biosciences, Llc	10 percent owner	4747 EXECUTIVE DRIVE, SUITE 210, SAN DIEGO CA 92121
Richard /ca/ Murray	director, officer: CEO and President	22643 WOODRIDGE CT, CUPERTINO CA 95014
Kevin C Tang	10 percent owner	4747 EXECUTIVE DRIVE, SUITE 210, SAN DIEGO CA 92121
Tang Capital Partners Lp	10 percent owner	4747 EXECUTIVE DRIVE, SUITE 210, SAN DIEGO CA 92121
Tang Capital Management Llc	10 percent owner	4747 EXECUTIVE DRIVE, SUITE 210, SAN DIEGO CA 92121
Hugh M Cole	officer: Chief Business Officer	C/O ARIAD PHARMACEUTICALS, INC, 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Elizabeth Trehu	officer: Chief Medical Officer	C/O JOUNCE THERAPEUTICS, INC., 1030 MASSACHUSETTS AVENUE, CAMBRIDGE MA 02138
Kimberlee C Drapkin	officer: CFO and Treasurer	PREDIX PHARMACEUTICALS HOLDINGS, INC., 4 MAGUIRE ROAD, LEXINGTON MA 02421
Third Rock Ventures Iii, L.p.	10 percent owner	29 NEWBURY STREET, 3RD FLOOR, BOSTON MA 02116
Jigar Raythatha	director	C/O JOUNCE THERAPEUTICS, INC., 780 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Third Rock Ventures Ii, L.p.	10 percent owner	29 NEWBURY STREET, 3RD FLOOR, BOSTON MA 02116
John Duncan Higgons	director	C/O AGIOS PHARMACEUTICALS, INC., 38 SIDNEY STREET, 2ND FLOOR, CAMBRIDGE MA 02139
Luisa Salter-cid	director	C/O GOSSAMER BIO, INC., 3013 SCIENCE PARK ROAD, SUITE 200, SAN DIEGO CA 92121
Gilead Sciences Inc	10 percent owner	333 LAKESIDE DR, FOSTER CITY CA 94404